期刊文献+

^(18)F-PSMA-1007 PET/CT最大标准摄取值预测高危险度前列腺癌 被引量:3

^(18)F-PSMA-1007 PET/CT maximum standard uptake value for predicting high risk stratification prostate cancer
下载PDF
导出
摘要 目的观察^(18)F-PSMA-1007 PET/CT最大标准摄取值(SUV_(max))预测高危险度前列腺癌(PCa)的价值。方法回顾性分析经病理证实且接受^(18)F-PSMA-1007 PET/CT检查的68例PCa患者,依据D'Amico危险分层标准将其分为低-中危组和高危组,比较组间各参数差异。以SUV_(max)构建高危PCa的Logistic回归模型,利用受试者工作特征(ROC)曲线评价其诊断效能。结果68例PCa的SUV_(max)为25.652(16.670,38.355);术前Gleason评分为8(7,9)分,术前平均总前列腺特异性抗原(tPSA)水平29.014(14.075,127.157)ng/ml。高危组(n=33)SUV_(max)为28.681(17.514,39.950)、tPSA为47.965(27.210,170.575)ng/ml,均高于低-中危组(n=35)的17.415(8.795,28.675)和13.345(6.958,18.443)ng/ml(P均<0.05)。以SUV_(max)建立的二分类Logistic回归模型预测高危PCa的ROC曲线下面积为0.773[95%CI(0.652,0.894)],截断值取0.78时,敏感度和特异度分别为81.62%和68.24%。结论^(18)F-PSMA-1007 PET/CT所示SUV_(max)可作为高危险度PCa的独立预测因子,为制定治疗方案及随访提供参考。 Objective To explore the value of^(18)F-PSMA-1007 PET/CT maximum standard uptake value(SUV_(max))for predicting high risk stratification prostate cancer(PCa).Methods Data of 68 patients PCa proved by biopsy pathology who underwent^(18)F-PSMA-1007 PET/CT scanning were retrospectively analyzed.According to D'Amico risk criteria,the patients were divided into low-medium risk group(n=35)and high risk group(n=33).Then relative parameters were compared between groups.A Logistic regression model for high risk PCa was established based on SUV_(max),and the diagnostic efficiency of this model was evaluated with receiver operating characteristic(ROC)curve analysis.Results The median SUV_(max)was 25.652(16.670,38.355),the median preoperative Gleason score was 8(7,9),and the median preoperative total prostate-specific antigen(tPSA)was 29.014(14.075,127.157)ng/ml of 68 cases of PCa.SUV_(max)was 28.681(17.514,39.950)and tPSA was 47.965(27.210,170.575)ng/ml in high risk group,higher than those in low-medium risk group(17.415[8.795,28.675]and 13.345[6.958,18.443]ng/ml,both P<0.05).The area under ROC curve of the Logistic regression model based on SUV_(max)was 0.773(95%CI[0.652,0.894]).Taken 0.78 as the cut-off value,the sensitivity and specificity was 81.62%and 68.24%,respectively.Conclusion SUV_(max)of^(18)F-PSMA-1007 PET/CT could be used as an independent predictor of high-risk PCa,hence providing references for treatment planning and following-up.
作者 白璐 郑安琪 李运轩 王卓楠 高俊刚 沈聪 高凡 段小艺 BAI Lu;ZHENG Anqi;LI Yunxuan;WANG Zhuonan;GAO Jungang;SHEN Cong;GAO Fan;DUAN Xiaoyi(Department of Medical Imaging,2.Clinical Research Center,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
出处 《中国医学影像技术》 CSCD 北大核心 2021年第9期1386-1390,共5页 Chinese Journal of Medical Imaging Technology
基金 西安交通大学第一附属医院临床研究项目(XJTU1AF-CRF-2020-008) 西安交通大学第一附属医院新医疗新技术(XJYFY-2019J1)。
关键词 前列腺肿瘤 正电子发射断层显像 危险度分层 prostatic neoplasms positron-emission tomography risk stratification
  • 相关文献

参考文献5

二级参考文献29

  • 1BRINKMAN M, REULEN R C, KELLEN E, et al. Are men with low selenium levels at increased risk of prostate cancer? [ J ]. Eur J Cancer, 2006, 42 (15): 2463-2471.
  • 2HEIDENREICH A, BASTIAN P J, BELLMUNT J, et al. EAU guidelines on prostate cancer, part 1 : screening, diagnosis, and local treatment with curative intent - update 2013 [ J]. Eur Urol, 2014, 65 (1): 124-137.
  • 3ROOBOL M J, VAN VUGT H A, LOEB S, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators [J]. Eur Urol, 2012, 61 (3) : 577 -583.
  • 4ROOBOL M J, ZHU X, SCHRODER F H, et al. A calculator for prostate cancer risk 4 years 'after an initially negative screen : findings from ERSPCrotterdam [J]. EurUrol, 2013, 63 (4): 627-633.
  • 5TOSOIAN J J, TROCK B J, LANDIS P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience [J]. J Clin Oncol, 2011, 29 (16) : 2185 -2190.
  • 6OTO A, YANG C, KAYHAN A, et al. Diffusion -weighted and dynamic contrast - enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis [J]. AJR Am J Roentgenol, 2011, 197 (6) : 1382 -1390.
  • 7PARTIN A W, KATI'AN M W, of prostate - specific antigen, topredict pathological stage multiinstitutional update [ J ] . SUBONG E N, et al. Combination clinical stage, and Gleason score of localized prostate cancer. A JAMA, 1997, 277 ( 18 ) : 1445- 1451.
  • 8GOMEZ VEIGA F, PONCE REIXA J, BARBAGELATA LOPEZ A, et al. Current role of PSA and other markers in the diagnosis of prostate cancer [J]. Arch Esp Urol, 59 (10) : 1069 -1082.
  • 9LORENZ A, ERMERT H, SOMMERFELD H J, et al. Ultrasound elastography of the prostate. A new technique for tumor detection [J]. UltraschallMed, 2000, 21 (1): 8-15.
  • 10NELSON E D, SLOTOROFF C B, GOMELLA LG, et al. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Geason score [ J ]. Urology, 2007, 70 (8): 1136-1140.

共引文献44

同被引文献12

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部